PolyPid Ltd. (PYPD) Research

PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.

Market snapshot

Symbol
PYPD
Price
$4.74
Day change
+3.95%
Market cap
$48.3M
P/E ratio
-3.09x
52-week range
3.06-5.21
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$9.50

Peer companies

  • Annovis Bio, Inc. (ANVS)
  • Actinium Pharmaceuticals, Inc. (ATNM)
  • BioAtla, Inc. (BCAB)
  • BioXcel Therapeutics, Inc. (BTAI)
  • Celularity Inc. (CELU)
  • Evaxion Biotech A/S (EVAX)
  • MAIA Biotechnology, Inc. (MAIA)
  • PDS Biotechnology Corporation (PDSB)

Recent insider activity

  • Jacobovitz Yitzchak Shlomo — trade (0 shares) on 2026-03-18
  • Stein Robert Benjamin — trade (312 shares) on 2023-08-05
  • Stein Robert Benjamin — trade (312 shares) on 2022-08-03
  • Stein Robert Benjamin — trade (6500 shares) on 2024-10-02
  • Stein Robert Benjamin — trade (14440 shares) on 2025-08-12

Open PolyPid Ltd. (PYPD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.